Cancer Chemotherapy and Pharmacology
-
Publication Venue For
-
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: Results of a first-in-man study.
75:851-859.
2015
-
TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts..
75:131-141.
2015
-
O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines..
60:883-889.
2007
-
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors..
59:139-147.
2007
-
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma..
58:634-639.
2006
-
Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity..
58:245-255.
2006
-
Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex..
57:135-144.
2006
-
Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient..
57:145-154.
2006
-
Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta..
56:585-593.
2005
-
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer..
55:559-564.
2005
-
The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH..
52:253-261.
2003
-
Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies..
51:459-464.
2003
-
Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells..
51:202-208.
2003
-
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer..
50:383-391.
2002
-
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study..
50:37-45.
2002
-
Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice..
48:413-416.
2001
-
Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts..
48:250-254.
2001
-
Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine..
48:47-52.
2001
-
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice..
48:83-87.
2001
-
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy..
47:327-332.
2001
-
Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice..
47:63-69.
2001
-
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts (vol 45, pg 345, 1999).
46:84-84.
2000
-
Camptothecin analogues with enhanced antitumor activity at acidic pH..
46:263-271.
2000
-
Erratum: Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts (Cancer Chemotherapy and Pharmacology 45 (345- 349)).
46:84.
2000
-
Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide..
45:335-344.
2000
-
O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials..
45:437-440.
2000
-
Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis..
46:19-26.
2000
-
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts..
45:345-349.
2000
-
A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma..
44:307-311.
1999
-
Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase..
43:80-85.
1999
-
Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR)..
43:73-79.
1999
-
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents..
41:485-490.
1998
-
Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial..
41:299-306.
1998
-
Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors..
42:479-482.
1998
-
Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft..
40:409-414.
1997
-
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea..
39:307-316.
1997
-
L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma..
39:179-186.
1997
-
Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial..
40:335-341.
1997
-
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors..
39:254-258.
1997
-
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts..
39:187-191.
1997
-
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies..
37:561-568.
1996
-
Carboplatin pharmacokinetics in young children with brain tumors..
38:395-400.
1996
-
Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta..
38:349-354.
1996
-
Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients..
38:425-430.
1996
-
Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines..
37:242-246.
1996
-
Cyclocreatine in cancer chemotherapy..
35:411-416.
1995
-
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors..
36:393-403.
1995
-
Phase I study of mitomycin C and menadione in advanced solid tumors..
36:293-298.
1995
-
The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft..
36:379-384.
1995
-
Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts..
34:171-174.
1994
-
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL..
35:121-126.
1994
-
Busulfan therapy of central nervous system xenografts in athymic mice..
35:127-131.
1994
-
Ifosfamide enantiomers: pharmacokinetics in children..
34:447-449.
1994
-
Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea..
35:161-164.
1994
-
Development of a model of melphalan-induced gastrointestinal toxicity in mice..
31:376-380.
1993
-
Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow..
33:10-16.
1993
-
Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line..
32:73-77.
1993
-
Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea..
32:471-476.
1993
-
Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas..
30:272-276.
1992
-
Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion..
30:226-228.
1992
-
Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin..
30:31-36.
1992
-
The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells..
31:23-31.
1992
-
Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study..
29:71-74.
1991
-
Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine..
28:15-21.
1991
-
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts..
27:278-284.
1991
-
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine..
27:258-262.
1991
-
Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency..
27:234-238.
1990
-
Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma..
26:223-226.
1990
-
High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity..
26:155-156.
1990
-
Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid..
26:159-162.
1990
-
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1..
26:383-386.
1990
-
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study..
23:377-383.
1989
-
Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma..
24:41-44.
1989
-
Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature..
21:347-350.
1988
-
Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease..
18:24-26.
1986